AU2019270404B2 - Blood biomarkers of stroke - Google Patents

Blood biomarkers of stroke Download PDF

Info

Publication number
AU2019270404B2
AU2019270404B2 AU2019270404A AU2019270404A AU2019270404B2 AU 2019270404 B2 AU2019270404 B2 AU 2019270404B2 AU 2019270404 A AU2019270404 A AU 2019270404A AU 2019270404 A AU2019270404 A AU 2019270404A AU 2019270404 B2 AU2019270404 B2 AU 2019270404B2
Authority
AU
Australia
Prior art keywords
leu
ala
ser
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019270404A
Other languages
English (en)
Other versions
AU2019270404A2 (en
AU2019270404A1 (en
Inventor
Emmanuelle Genin
Serge Timsit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Etablissement Francais du Sang
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Etablissement Francais du Sang
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Etablissement Francais du Sang, Centre Hospitalier Regional et Universitaire de Brest, Univerdite de Bretagne Occidentale filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2019270404A1 publication Critical patent/AU2019270404A1/en
Publication of AU2019270404A2 publication Critical patent/AU2019270404A2/en
Application granted granted Critical
Publication of AU2019270404B2 publication Critical patent/AU2019270404B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2019270404A 2018-05-16 2019-05-16 Blood biomarkers of stroke Active AU2019270404B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16
EP18305600.1 2018-05-16
PCT/EP2019/062653 WO2019219831A1 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Publications (3)

Publication Number Publication Date
AU2019270404A1 AU2019270404A1 (en) 2020-12-10
AU2019270404A2 AU2019270404A2 (en) 2020-12-17
AU2019270404B2 true AU2019270404B2 (en) 2025-04-17

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019270404A Active AU2019270404B2 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Country Status (13)

Country Link
US (1) US12247257B2 (https=)
EP (1) EP3794355A1 (https=)
JP (2) JP7463351B2 (https=)
KR (1) KR20210049026A (https=)
CN (1) CN112424609A (https=)
AU (1) AU2019270404B2 (https=)
BR (1) BR112020023259A2 (https=)
CA (1) CA3100171A1 (https=)
IL (1) IL278666B2 (https=)
MA (1) MA52617A (https=)
MX (1) MX2020012297A (https=)
SG (1) SG11202011369VA (https=)
WO (1) WO2019219831A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
JP2023111774A (ja) * 2022-01-31 2023-08-10 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
WO2025151599A1 (en) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Rna-based method for stroke assessment and treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104393A1 (en) * 2000-11-28 2003-06-05 Sharp Frank R. Blood assessment of injury

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US9410204B2 (en) 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
JP2016507235A (ja) * 2013-02-01 2016-03-10 ウエストバージニア ユニバーシティＷｅｓｔ Ｖｉｒｇｉｎｉａ Ｕｎｉｖｅｒｓｉｔｙ 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法
US11021750B2 (en) * 2013-10-13 2021-06-01 The Research Foundation For State University Of Newyork Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
US20190311789A1 (en) * 2016-10-03 2019-10-10 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104393A1 (en) * 2000-11-28 2003-06-05 Sharp Frank R. Blood assessment of injury

Also Published As

Publication number Publication date
MA52617A (fr) 2021-03-24
KR20210049026A (ko) 2021-05-04
EP3794355A1 (en) 2021-03-24
SG11202011369VA (en) 2020-12-30
AU2019270404A2 (en) 2020-12-17
IL278666B1 (en) 2025-02-01
US20210214793A1 (en) 2021-07-15
JP2021523744A (ja) 2021-09-09
AU2019270404A1 (en) 2020-12-10
MX2020012297A (es) 2021-03-25
JP2024075761A (ja) 2024-06-04
IL278666A (en) 2020-12-31
BR112020023259A2 (pt) 2021-02-23
US12247257B2 (en) 2025-03-11
JP7463351B2 (ja) 2024-04-08
CA3100171A1 (en) 2019-11-21
WO2019219831A1 (en) 2019-11-21
IL278666B2 (en) 2025-06-01
CN112424609A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
AU2019270404B2 (en) Blood biomarkers of stroke
US9803243B2 (en) Biomarkers for diagnosis of stroke and its causes
US11136626B2 (en) Biomarkers for the diagnosis of lacunar stroke
KR20080016789A (ko) 혈액 림프구에서 자궁내막증을 진단할 수 있는 분자마커의동정
JP2008537474A5 (https=)
US11021750B2 (en) Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
JP6784673B2 (ja) 膵臓がんに冒された患者の生存予後を判断する方法
RU2821748C2 (ru) Способы диагностики инсульта, эффективности терапии, определения риска инсульта
JP2023157965A (ja) アトピー性皮膚炎の検出方法
CN116635526A (zh) 特应性皮炎的重症度的检测方法
US10975436B2 (en) Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
JP7847450B2 (ja) アトピー性皮膚炎の症度悪化の検出方法
JP7847451B2 (ja) アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
JP7767500B2 (ja) アトピー性皮膚炎の重症度の検出方法
Fabrice et al. Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents
KR20250068515A (ko) 파킨슨병의 진단, 예후 예측, 또는 치료용 턱밑샘 조직 바이오마커, 및 이를 이용한 파킨슨병 진단, 또는 예후 예측 방법, 및 파킨슨병 치료 물질 스크리닝 방법
Cockayne et al. Whole blood gene expression and serum biomarker profiling in a COPD cohort identifies markers related to neutrophilic inflammation, wound healing and altered b cell signaling
WO2009097080A1 (en) Protein phosphatase-1 inhibitor-1 polymorphism and methods of use
CN111356773A (zh) 诊断慢性阻塞性肺疾病的炎性表型的方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 20 NOV 2020

FGA Letters patent sealed or granted (standard patent)